United States Patent 3,725,548: Scope, Claims, Expiration, and Sulindac Patent Landscape

U.S. Patent No. 3,725,548 is an early Merck patent covering anti-inflammatory indene-acetic acid compounds, methods of treating pain, fever, and inflammation, and pharmaceutical compositions containing those compounds. The claims supplied identify cis-5-fluoro-2-methyl-1-(p-methylsulfinylbenzylidene)-3-indene acetic acid, the active ingredient later known as sulindac, together with related fluoro, chloro, methoxy, difluoro, and propionic-acid analogs.

The patent is expired. It does not provide current U.S. patent exclusivity for sulindac, generic sulindac products, or products containing the specifically named compounds. Its historical importance is as an early compound and use patent in the sulindac development program, not as a current barrier to generic entry.

What does U.S. Patent 3,725,548 cover?

The patent covers three principal subject-matter categories:

Methods of treating pain, fever, or inflammation.
Pharmaceutical compositions containing the claimed indene derivatives.
Specifically identified substituted indene-acetic acid compounds, including the cis form of sulindac.

The supplied claims do not include the text of claims 1, 2, 3, 11, 12, or 13's structural formulas. Those missing formulas are important because they likely define the broader Markush genus from which the narrower named-compound claims depend. The named compounds, however, permit a reliable analysis of the principal chemical scope.

What chemical scaffold is claimed?

The core scaffold is an indene derivative containing:

A 2-methyl substituent;
A 3-acetic acid or related propionic-acid side chain;
A benzylidene substituent at the indene ring;
A para-methylsulfinyl group on the benzylidene phenyl ring;
Halogen or methoxy substitution on the indene nucleus;
In at least one claim, a defined cis configuration.

The best-known compound in the claims is:

cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]-3-indene acetic acid

This compound is sulindac, an orally administered nonsteroidal anti-inflammatory drug. Sulindac is a prodrug that is metabolized to an active sulfide metabolite.

What compounds are expressly identified?

Claim	Compound or subject matter	Principal limitation
4	5,6-Difluoro analog	Two fluoro substituents
5	5-Fluoro analog	One fluoro substituent
6	Alpha-(5-fluoro analog)-propionic acid	Propionic-acid side chain
7	5,7-Difluoro analog	Fluoro substitution at positions 5 and 7
8	5-Chloro analog	Chloro substitution
9	6-Fluoro-5-methoxy analog	Fluoro and methoxy substitution
10	Cis-5-fluoro compound	Method-of-treatment claim
14-19	Named compounds in composition claims	Composition claims
20	Cis-5-fluoro compound	Composition with pharmaceutically acceptable carrier

The terminology in the patent uses older chemical nomenclature. Modern references generally identify the principal compound as sulindac or sulindac free acid.

How do the method-of-treatment claims operate?

Claims 2 through 10 are treatment claims directed to administering a therapeutically effective amount of a claimed compound to a host for pain, fever, or inflammation.

The principal legal limitations are:

A therapeutic purpose;
Administration to a host or patient;
A therapeutically effective amount;
Use of a claimed indene derivative;
In claim 10, the cis form of the 5-fluoro compound.

These claims are narrower than a general claim to any anti-inflammatory use. They require both the claimed chemical identity and the specified therapeutic application.

What does claim 10 protect?

Claim 10 is the clearest named-compound method claim. It covers:

Treating pain, fever, or inflammation by administering a therapeutically effective amount of cis-5-fluoro-2-methyl-1-(p-methylsulfinylbenzylidene)-3-indene acetic acid.

A product that uses a different active ingredient would not literally fall within claim 10. A product using the same active ingredient for a different indication could still raise infringement issues if the product labeling, prescribing instructions, or conduct supported the claimed therapeutic use. Those issues would have been relevant during the patent term, but they have no current enforcement significance because the patent expired.

Are these claims product claims?

No. Claims 2 through 10, as supplied, are method claims. They do not directly claim the compound as a composition of matter. They require performance of the treatment method.

That distinction matters because compound claims generally provide stronger exclusionary coverage than method claims. A method claim can be avoided by changing the use, although induced infringement and label-based theories can affect the analysis during the enforceable term.

What do the pharmaceutical composition claims cover?

Claims 11 through 20 cover pharmaceutical compositions containing the claimed compounds and a pharmaceutically acceptable carrier.

Claim 20 is the clearest composition claim:

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and cis-5-fluoro-2-methyl-1-(p-methylsulfinylbenzylidene)-3-indene acetic acid.

The composition claims could cover formulations such as:

Tablets;
Capsules;
Powders;
Oral suspensions;
Other conventional dosage forms containing the claimed active ingredient and a pharmaceutically acceptable excipient.

The supplied claims do not identify a particular tablet coating, release profile, particle size, salt, polymorph, dissolution specification, or manufacturing process. They therefore do not read as modern formulation-specific claims. Their apparent scope is directed primarily to the active compound in a pharmaceutical carrier.

Are there formulation patents in this patent?

No separate formulation technology is apparent from the supplied claims. The claims do not require:

Enteric coating;
Sustained release;
Controlled release;
A specific excipient;
A defined dissolution profile;
A particular dosage strength;
A specific crystalline form;
A salt or solvate;
A defined particle-size distribution.

The patent should therefore be classified as a compound/use and basic composition patent, not as a specialized drug-delivery patent.

How should the dependent claims be interpreted?

The supplied claim text presents claims 14 through 19 as sequential dependencies:

Claim 15 depends on claim 14;
Claim 16 depends on claim 15;
Claim 17 depends on claim 16;
Claim 18 depends on claim 17;
Claim 19 depends on claim 18.

Read literally, that sequence would create chemical inconsistencies. For example, a claim directed to the 5-fluoro compound could not ordinarily depend on a claim limited to the 5,6-difluoro compound while also narrowing to a different compound. The same issue appears in claims 16 through 19.

This indicates that the supplied text may contain OCR, transcription, or formatting errors. The original issued patent should control the dependency analysis. The substance of the claims indicates that the patent intended to list separately narrowed species within a broader composition claim structure, not create a cumulative chain requiring every different substituent simultaneously.

When did U.S. Patent 3,725,548 expire?

U.S. Patent No. 3,725,548 was issued under the pre-1995 U.S. patent-term regime. Patents of this type generally received 17 years from issuance, subject to any terminal disclaimer or special adjustment.

On that basis, the patent's ordinary term ended in approximately 1990, about 17 years after its 1973 issuance. It is therefore long expired and cannot currently block:

Generic sulindac tablets;
Generic sulindac capsules;
Sulindac active pharmaceutical ingredient;
Sulindac-containing pharmaceutical compositions;
Use of the named compounds for pain, fever, or inflammation.

The patent also predates the modern 20-year-from-earliest-effective-filing-date term established by the Uruguay Round Agreements Act. Patent-term analysis should therefore use the historical issuance-based regime, not the current 20-year rule. [1]

Exclusivity timeline

Event	Approximate timing	Commercial significance
Patent issued	1973	U.S. patent rights began
Patent term under historical rule	17 years from issuance	Ordinary term basis
Approximate expiration	1990	Compound and use claims ceased to be enforceable
Sulindac FDA approval	1978	U.S. commercial launch period
Generic availability	Later commercial period	Generic entry no longer constrained by this patent
Current status	Expired	No active patent exclusivity

The exact expiration date should be taken from the USPTO patent record and any applicable terminal-disclaimer or adjustment records. The conclusion is unchanged: the patent is not an active U.S. exclusivity right.

What is the FDA and Orange Book status of sulindac?

Sulindac was approved by FDA under the brand name Clinoril. The active ingredient is sulindac, and the approved drug is an NSAID used for conditions including osteoarthritis and rheumatoid arthritis. FDA-approved sulindac products have historically included oral tablet dosage forms. [2]

Sulindac is not a biologic. Biosimilar law is therefore not relevant. The applicable competitive pathway is the abbreviated new drug application, or ANDA, for a generic product demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug.

Does the patent have current Orange Book significance?

No. U.S. Patent 3,725,548 is not a current Orange Book barrier. The Orange Book lists patents submitted for approved drug products, but a patent that expired decades ago does not create a present patent hold on generic approval or launch. FDA approval status and patent enforceability are separate issues. [3]

Any current Orange Book analysis would need to focus on patents associated with the relevant reference product and the particular marketed dosage form. The 1973 patent itself is not an enforceable modern listing against generic sulindac.

Were Paragraph IV challenges relevant?

Paragraph IV certifications are relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. They are not a current issue for U.S. Patent 3,725,548 because the patent expired long ago.

Historically, a generic applicant could have addressed an unexpired listed patent through:

Paragraph IV certification;
Paragraph III certification agreeing to wait until expiration;
A section viii statement carving out a patented method of use;
A patent-law challenge after filing.

For the claims supplied, a Paragraph IV dispute could historically have focused on:

Whether the generic contained the claimed cis compound;
Whether the composition included the required carrier and active ingredient;
Whether the product labeling induced the claimed method of treatment;
Whether the claims were invalid for anticipation or obviousness;
Whether the claims were enforceable in view of prosecution history or term status.

Those issues are now historical because the patent term has ended.

How strong was the patent estate for sulindac?

The patent had meaningful historical value because it combined several layers of protection:

A broad chemical genus, apparently set out in the missing formula claims;
Named chemical species;
Treatment methods;
Pharmaceutical compositions;
A specific cis compound corresponding to sulindac.

Its strongest claims were likely the species and composition claims directed to the specific sulindac structure. The treatment claims were more dependent on proving the claimed use and administration. The broad genus claims would have faced the greatest validity risk if the prior art disclosed related indene-acetic acid compounds or predictable substitutions.

Historical strength by claim category

Claim category	Historical strength	Main vulnerability
Broad Markush compounds	Moderate	Prior-art genus and obviousness challenges
Named chemical species	Stronger	Anticipation, enablement, and characterization issues
Method claims	Moderate	Use and induced-infringement limitations
Composition claims	Moderate to strong	Conventional-carrier and obviousness arguments
Cis-specific claim	Strong if stereochemistry was novel and enabled	Prior art and stereochemical disclosure

The patent did not appear to include modern protection for polymorphs, salts, formulations, metabolites, dosing regimens, or manufacturing processes. Its protection was concentrated in the active chemical structure and basic therapeutic use.

What manufacturing and intellectual-property barriers existed?

During the patent term, a competitor faced several potential barriers:

The active compound's chemical synthesis;
Control of the benzylidene stereochemistry;
Preparation of the methylsulfinyl substituent;
Purification and characterization of the active ingredient;
Reproduction of an acceptable oral dosage form;
Avoidance of the composition and treatment claims.

The patent claims do not expressly cover a manufacturing process. A competitor might therefore have attempted a noninfringing synthesis even during the patent term, provided the resulting product did not fall within an enforceable product, composition, or use claim.

Today, the principal barriers are regulatory and commercial rather than patent-based. They include:

API sourcing;
FDA quality requirements;
Bioequivalence;
Manufacturing economics;
Product liability;
Market size;
Competition from established generic suppliers.

How does sulindac compare with competing NSAIDs?

Sulindac competed historically with indomethacin, naproxen, ibuprofen, diclofenac, and other NSAIDs. Its patent estate was structurally different from that of newer products because the key patent was an early composition and use patent rather than a later lifecycle estate centered on release technology, salts, polymorphs, or combination products.

Drug	General class	Principal historical patent issue	Current patent posture
Sulindac	Indene-acetic acid NSAID	Early compound, use, and composition claims	Original estate expired
Indomethacin	Indole-acetic acid NSAID	Early compound and formulation rights	Original estate expired
Naproxen	Propionic-acid NSAID	Compound and chiral-product protection	Original core rights expired
Ibuprofen	Propionic-acid NSAID	Compound and process rights	Original core rights expired
Diclofenac	Phenylacetic-acid NSAID	Compound, salts, formulations	Core rights expired; later products varied

Sulindac's commercial position is therefore governed mainly by generic supply and product demand rather than patent exclusivity.

What litigation and settlement risks remain?

No current litigation risk arises from enforcement of U.S. Patent 3,725,548 because the patent is expired. Any historical litigation, licensing, or settlement associated with the patent would not restore exclusivity.

A current company evaluating sulindac should instead review:

Active patents listed for the relevant FDA reference product;
Trademarks and trade dress;
Regulatory exclusivity;
Manufacturing know-how;
API supplier agreements;
Product liability exposure;
Patent rights covering combination products or new delivery systems.

There is no basis in the supplied claims for a current biosimilar dispute, biologic patent thicket, or active Paragraph IV settlement tied to this patent.

What licensing deals were associated with the patent?

The claims identify the technology as part of the Merck-era sulindac development program. The supplied material does not establish a current licensing agreement, assignment chain, royalty arrangement, or settlement involving U.S. Patent 3,725,548.

A historical assignment or license would not affect the patent's present status after expiration. Any commercial evaluation should treat this patent as expired background IP rather than a licensable exclusionary asset.

What is the commercial significance of the patent today?

The patent has no current revenue-protection value. It cannot support:

Patent-based price premiums;
Delayed generic entry;
Royalty demands based on continued patent validity;
ANDA litigation leverage;
Current Orange Book exclusivity;
Product-specific biosimilar control.

Its remaining value is historical and analytical. It helps identify the original chemical and therapeutic concept behind sulindac and illustrates the early patent strategy for NSAID development.

Key Takeaways

U.S. Patent No. 3,725,548 covers indene-acetic acid NSAIDs, including sulindac and related fluoro, chloro, methoxy, difluoro, and propionic-acid analogs.
The claims include treatment methods and pharmaceutical compositions, not only chemical compounds.
Claim 10 specifically targets cis-sulindac for treating pain, fever, or inflammation.
Claim 20 covers a pharmaceutical composition containing cis-sulindac and a pharmaceutically acceptable carrier.
The supplied dependency sequence for claims 14 through 19 appears corrupted or transcribed inaccurately and should not be treated as the authoritative claim structure.
The patent expired approximately 17 years after its 1973 issuance, around 1990.
It creates no current U.S. patent barrier to generic sulindac.
It is not a current biosimilar or Paragraph IV risk.
The patent does not show modern formulation, polymorph, salt, dosage-regimen, or manufacturing-process protection.
Current commercial risk is primarily regulatory, manufacturing, and market-based.

FAQs

Does U.S. Patent 3,725,548 still protect Clinoril?

No. The patent expired decades ago and does not currently protect Clinoril or generic sulindac products.

Is sulindac protected by a biologic patent or biosimilar pathway?

No. Sulindac is a small-molecule NSAID. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.

Did the patent claim sulindac's active sulfide metabolite?

The supplied claims identify sulindac and related indene derivatives. They do not expressly claim the active sulfide metabolite as a separate metabolite claim.

Can a company manufacture sulindac without licensing this patent?

Yes, the expired patent does not require a current license. Separate rights involving trademarks, manufacturing contracts, active formulations, or other later patents must be evaluated independently.

Are the named analogs in claims 4 through 9 separately protected today?

No. Any patent protection arising solely from U.S. Patent 3,725,548 ended with the patent's expiration.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term provisions. https://www.uspto.gov
U.S. Food and Drug Administration. (n.d.). Clinoril (sulindac) prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
United States Patent and Trademark Office. (1973). U.S. Patent No. 3,725,548. Washington, DC: U.S. Department of Commerce.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	193345	⤷ Start Trial
Austria	312585	⤷ Start Trial
Austria	313263	⤷ Start Trial
Austria	315826	⤷ Start Trial
Austria	321291	⤷ Start Trial
Austria	326647	⤷ Start Trial
Austria	327182	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 3,725,548

Summary for Patent: 3,725,548